《异动股》同方康泰(01312.HK)飙升1倍挑战牛熊线 成交为多年罕见
将於8月28日放榜的同方康泰(01312.HK)无惧早前盈警,今天价量齐异动,股价曾重越牛熊线(0.148元),最高见0.149元,现造0.147元,飙升1倍,一向稀疏成交激增至3.076亿股,为近几年罕见,涉资3,800万元。
该公司主要於内地制销处方药(包括化学药及传统中医药)、经营健身中心及提供相关谘询服务及经营特许业务以获得特许权费及服务费收入、制销水泥和熟料与买卖水泥及提供技术服务。
该公司6月4月发布补充盈警通告预计,受累新冠肺炎疫情大流行,截至2020年3月止首季业绩将录得综合除税前亏损800-980万元,扭转上年同期录得溢利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.